Results 21 to 30 of about 192,885 (309)
Research progress of single-cell sequencing in neoadjuvant chemotherapy for triple-negative breast cancer [PDF]
Zhongguo aizheng zazhi, 2021 Triple-negative breast cancer is the most invasive and malignant type of breast cancer. At present, therapy for triple-negative breast cancer is the comprehensive treatment regimens based on chemotherapy, in which neoadjuvant chemotherapy plays an ...
HU Xi’e , YANG Zhenyu , XUE Jingyi , YANG Ping , PENG Shujia , YUAN Lijuan , BAO Guoqiang
doaj +1 more source
Asian Pacific Journal of Cancer Prevention, 2014 Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed.
Idil, Cetin, Mehmet, Topcul
openaire +3 more sources
Male Triple-Negative Breast Cancer [PDF]
Cureus, 2021 Male breast cancer is a rarely encountered disease, when compared with female breast cancer, often detected in more advanced stage at the time of diagnosis, and associated with more lymph node metastasis rates, more estrogen receptors positivity, and less human epidermal growth factor receptor-2 expression (HER-2) rates.
Qavi, Qasif +4 more
openaire +2 more sources
Therapies for triple negative breast cancer [PDF]
Expert Opinion on Pharmacotherapy, 2015 Triple negative breast cancer (TNBC) is a heterogeneous disease associated with a high risk of recurrence, and therapeutic options are currently limited to cytotoxic therapy. Germ-line mutations may occur in up to 20% of unselected patients with TNBC, which may serve as a biomarker identifying which patients may have tumors that are particularly ...
Eleni, Andreopoulou +3 more
openaire +2 more sources
Technology in Cancer Research & Treatment, 2021 Triple-negative breast cancer is a heterogeneous disease with different molecular and histological subtypes. The Androgen receptor is expressed in a portion of triple-negative breast cancer cases and the activation of the androgen receptor pathway is ...
Taobo Hu +3 more
doaj +1 more source
Archives of Medical Science, 2019 Introduction Medullary breast cancer (MdBC) is an uncommon type of breast cancer representing 1–7% of all cases. It is characterized by the occurrence of many histopathological features associated with a high grade of malignancy.
Michał P. Budzik +6 more
doaj +1 more source
Progress of Immunotherapy and Its Application in Triple Negative Breast Cancer
Zhongliu Fangzhi Yanjiu, 2020 In recent years, potential new therapeutic options have been yielded for the immunotherapy of invasive cancers. The most important breakthrough in breast cancer research today is to understand the immune features and profiles of triple negative breast ...
ZHENG Hongmei +6 more
doaj +1 more source
Frontiers in Oncology, 2023 Triple-negative breast cancer refers to breast cancer patients with negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2).
Ruoyan Qin +6 more
doaj +1 more source
Triple Negative Breast Cancer – An Overview [PDF]
Hereditary Genetics, 2012 Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene.
Aysola, Kartik +12 more
openaire +2 more sources
Technology in Cancer Research & Treatment, 2023 Breast cancer is the most common malignancy and the second most common cause of cancer-related mortality in women. Triple-negative breast cancers do not express estrogen receptors, progesterone receptors, or human epidermal growth factor receptor 2 and ...
Boya Lu MD +3 more
doaj +1 more source